share_log

Regulus Therapeutics Q4 EPS $(0.40) Misses $(0.39) Estimate

Regulus Therapeutics Q4 EPS $(0.40) Misses $(0.39) Estimate

Regulus Therapeutics第四季度每股收益美元(0.40)未达到预期(0.39美元)
Moomoo 24/7 ·  03/21 16:08

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) by 2.56 percent. This is unchanged from the same period last year.

Regulus Therapeutics(纳斯达克股票代码:RGLS)公布的季度亏损为每股0.40美元,比分析师普遍预期的0.39美元(0.39美元)低2.56%。这与去年同期相比没有变化。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发